What "Cancer Vaccine" Actually Means
Correction: An earlier version of this article introduced routine adult vaccination as the other side of the phrase "cancer vaccine," and linked to our article on shots with an age line after 50. Those shots — shingles, flu, COVID, RSV — are not cancer prevention vaccines, and none of the sources cited here address them. The comparison has been removed. Corrected August 29, 2026.
The phrase “cancer vaccine” does a lot of work for two words. It covers products given to people who already have cancer. It also has to carry cancer prevention vaccines, which NCI names as a separate category. Those are not two versions of the same thing.
A cancer treatment vaccine is given to people who already have cancer. NCI draws the line plainly: these vaccines “work against cancer cells, not against something that causes cancer.” Cancer prevention vaccines are the other category NCI names. NCI describes three main ways treatment vaccines are made, and the approved uses on its drug pages are narrow.
Two Different Things Share One Word
NCI puts treatment vaccines inside immunotherapy — treatments that strengthen the body’s own defenses against a cancer that already exists. That sentence is the dividing line. Routine adult vaccination is a separate subject, and which shots have an age line after 50 is where it lives.
The idea underneath a treatment vaccine is simple enough. Cancer cells carry substances called tumor-associated antigens that normal cells don’t have, or have at lower levels. The vaccine helps the immune system learn to recognize those antigens and destroy the cells carrying them.
Treatment vaccines are one type of immunotherapy among several, alongside immune checkpoint inhibitors, T-cell transfer therapy, and monoclonal antibodies. That is worth holding onto when you read the news. A story about immunotherapy is often not a story about vaccines at all.
The Three Ways NCI Describes
NCI says cancer treatment vaccines may be made in three main ways, and describes what each one means. The differences come down to starting material — what goes into the vaccine — and NCI’s own gloss stays close to that.
How NCI describes the three ways cancer treatment vaccines can be made
| Made from | What NCI says that means |
|---|---|
| The patient’s own tumor cells | “Custom-made so that they cause an immune response against features that are unique to your cancer” |
| Tumor-associated antigens found on cancer cells of many people with a specific type of cancer | “Can cause an immune response in any patient whose cancer produces that antigen” |
| The patient’s own dendritic cells, a type of immune cell | “Stimulate your immune system to respond to an antigen on tumor cells” |
The second column is where the trade-off shows up. One route is built around a single person’s cancer. Another is built around an antigen that many people’s cancers share.
The column pairs each starting material with the immune response NCI attaches to it.
Two Products With an Approved Use on the Page
Sipuleucel-T, sold under the brand name Provenge, has its own NCI drug page, and that page carries an FDA Approved field reading Yes. The page states the approved use this way: “Prostate cancer that has metastasized (spread to other parts of the body). It is used in men who have few or no symptoms and whose cancer is hormone-refractory (does not respond to hormone treatment).”
Talimogene laherparepvec, sold as Imlygic, has a page with the same field and the same answer. Its approved use reads: “Melanoma in the skin and lymph nodes that cannot be removed by surgery. It is used as local treatment in patients whose disease has come back after being treated with surgery.”
A lot sits inside each of those sentences. Not prostate cancer, but prostate cancer that has spread, in men with few or no symptoms, whose cancer no longer responds to hormone treatment. Not melanoma, but melanoma in skin and lymph nodes that surgery cannot remove, in patients whose disease returned after surgery.
Those qualifiers are the actual content. A headline saying a cancer vaccine is approved is technically accurate and tells you almost nothing about who it is for.
A Virus Therapy That Sits Beside the Category
Talimogene laherparepvec is worth a second look, because NCI is careful about where it belongs. NCI calls oncolytic virus therapy “a different type of cancer treatment” that is “sometimes described as a type of cancer treatment vaccine.” That hedge is doing real work, and summaries drop it.
An oncolytic virus infects and breaks down cancer cells without harming normal cells. Talimogene laherparepvec is based on herpes simplex virus type 1. The virus can infect both cancer and normal cells, but normal cells are able to kill it and cancer cells cannot.
It is injected directly into a tumor. As the virus makes more copies of itself, the cancer cells burst and die, and the dying cells release new viruses and other substances that can prompt an immune response against cancer cells elsewhere in the body.
So it can end up doing something a vaccine does — prompting the immune system to react — by a route that isn’t a vaccine’s. NCI’s “sometimes described as” is more precise than the shorthand.
Two Small Trials and What They Did Not Settle
An NCI blog post dated April 23, 2025 reports two small clinical trials of personalized neoantigen treatments: one in kidney cancer with nine patients, one in pancreatic cancer with 16. In both, the vaccines were built for each individual patient from genetic analysis of tumor tissue taken during surgery, then given in the months after that surgery.
Neoantigens are mutated proteins on a person’s cancer cells. They can work like an alarm telling the immune system that those cells are threats. The alarm often fails, for different reasons, and these treatments are designed to fill that gap.
Immune checkpoint inhibitors were part of both trials. In the kidney trial, five of the nine participants also received a low dose of one with each treatment dose; in the pancreatic trial, patients were given a single dose at the time of their first vaccine dose, followed by multiple vaccine doses over several months and then a short course of a four-drug chemotherapy regimen. Checkpoints are a normal part of the immune system, there to keep an immune response from getting strong enough to damage healthy tissue. When a checkpoint protein on a T cell binds its partner protein on another cell, the pair sends an “off” signal to the T cell.
Checkpoint inhibitors block that binding, so the “off” signal never arrives and the T cell can attack. One such drug acts against a protein called CTLA-4. Others act against PD-1 or its partner PD-L1.
Eight of the 16 pancreatic cancer patients had a strong immune response, and six of them remained cancer-free about three years later. In the kidney trial, no patient had a recurrence. The post’s own summary is that the treatments “appeared to prevent cancer from returning in patients who had successful surgery to remove their tumors.” The hedge is the post’s, and it carries the weight.
Here is the caution NCI prints alongside the result, and it deserves to travel with the number. It is unclear whether the immune-based treatment is what accounts for the absence of recurrences in the kidney trial. It is not unusual for people with operable kidney cancer to live several years or longer after surgery without their cancer coming back.
Side effects reported in both studies were mild. The research teams said they are optimistic, and also said that larger clinical trials are needed to confirm these initial results. That second statement is theirs too, and it is not a formality.
Reading the Word Carefully
What survives all this is narrower than the phrase suggests, and more interesting for it. Three described routes for making a treatment vaccine, each defined by its starting material. Products whose NCI pages state an approved use state it for one specific situation. And early trial work whose own researchers say larger trials are needed to confirm the initial results.
The gap between that and the phrase “cancer vaccine” is where most confusion lives. A treatment vaccine is not a shot you get to avoid a disease. A promising early result in a trial of nine patients, or of sixteen, is not the same as a treatment available to point to.
The two questions that separate these stories from each other are whether the people in them already have cancer, and how many of them there were.
This article is general information, not professional advice. For decisions about your money or health, consult a qualified professional.